| Document |
Document Title |
|
WO/2010/091185 |
The invention is directed to a compound according to formula (I). The compounds of formula (I) include prodrugs, pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof. The invention is also directed to a pharm...
|
|
WO/2010/089213 |
The invention relates to a method for producing aldehydes and ketones from easily accessible primary and secondary alcohols by oxidation with atmospheric oxygen or pure oxygen using a catalyst system which consists of a derivative of a f...
|
|
WO/2010/090304 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
|
WO/2010/087727 |
The present invention relates to enaminocarbonyl compounds with the formula I, in which X denotes O or CH2, Y denotes N and each of R1 and R2 denotes hydrogen, or Y denotes a CH and either R1 or R2 denotes a C1-4 alkyl, and the remaining...
|
|
WO/2010/085968 |
The present invention provides compounds of formula (I) wherein R1 is a monocyclic 5- or 6 membered heteroaryl; R4 is a monocyclic 5- or 6 membered heteroaryl and the other substituents as defined in the claims, that inhibit cell prolife...
|
|
WO/2010/088450 |
Provided herein are compounds, compositions, and methods for treating or ameliorating diseases associated with the modulation of SERCA.
|
|
WO/2010/086878 |
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta. Further, the present invention relates to processes of prepari...
|
|
WO/2010/088450 |
Provided herein are compounds, compositions, and methods for treating or ameliorating diseases associated with the modulation of SERCA.
|
|
WO/2010/087430 |
An N-acyl anthranilic acid derivative represented by general formula (I) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl grou...
|
|
WO/2010/086366 |
The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; m free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
|
|
WO/2010/083722 |
A process for one-pot synthesis of Corey lactone, characterized in that it comprises selecting 2-halo-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid and ester derivatives having the formula I as raw material, adding oxidant, alkalizing wit...
|
|
WO/2010/085352 |
The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, fu...
|
|
WO/2010/085352 |
The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, fu...
|
|
WO/2010/084797 |
Disclosed is a hetero atom-containing compound which has an excellent activity as an α2δ ligand. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R...
|
|
WO/2010/083597 |
There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well as compositions comprising Lubiprostone and other compounds, includ...
|
|
WO/2010/081894 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/082278 |
Disclosed is a method for producing a (meth)acrylic acid ester, including reacting an alcohol (A) represented by formulae (2) to (5) with an acid anhydride (B) such as (meth)acrylic acid anhydride (B1) in the presence of a catalyst conta...
|
|
WO/2010/079828 |
Provided is a pentacene adduct wherein a leaving group has been selectively added to the second ring (positions 5, 14) from the end of a pentacene skeleton. Said pentacene adduct can be manufactured by Diels-Alder addition of a leaving g...
|
|
WO/2010/080290 |
A process is provided for the synthesis of furan and related compounds by vapor phase decarbonylation of furfural and derivatives, using a palladium/alumina catalyst that has been promoted with an alkali carbonate. Catalyst lifetime is i...
|
|
WO/2010/080414 |
Compounds of Formulas I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.
|
|
WO/2010/080537 |
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
|
|
WO/2010/080414 |
Compounds of Formulas I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.
|
|
WO/2010/076033 |
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspe...
|
|
WO/2010/075887 |
Provided herein are compounds and methods useful for preparing hexahydrofuro[2,3-b]furan-3-ol. Hexahydrofuro[2,3-b]furan-3-ol can be efficiently synthesized in four steps from readily available starting materials.
|
|
WO/2010/075869 |
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)- mediated transcription and signaling under hypoxic conditions. In one asp...
|
|
WO/2010/076878 |
Disclosed is an organic electroluminescent element material which has a 2,7-di-substituted naphthalene ring in the molecule. Also disclosed is an organic electroluminescent element comprising a cathode, an anode, and an organic thin fil...
|
|
WO/2010/076034 |
The present invention provides compounds of formula (I), wherein R1 is a monocyclic 5- or 6-membered heteroaryl; R4 is phenyl or monocyclic 5- or 6-membered heteroaryl; and the other substituents as defined in the claims, that inhibit ce...
|
|
WO/2010/076033 |
The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspe...
|
|
WO/2010/075437 |
The present invention relates to systems and methods for producing fuels and fuel precursors from carbohydrates. In an embodiment the invention includes a method of producing 5-hydroxymethylfurfural (HMF), including contacting a sacchari...
|
|
WO/2010/072770 |
The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition ...
|
|
WO/2010/074272 |
Provided is a method whereby a heteroaromatic ring aryl can be very rapidly methylated at a high yield. In an N-alkyl-2-pyrrolidinone, a heteroaromatic ring aryltrialkylstannan is cross-coupled with methyl iodide in the presence of a pal...
|
|
WO/2010/074087 |
Disclosed is an organic electroluminescent element which is characterized by comprising a cathode, an anode, and a monolayered or multilayered organic thin film layer, wherein the organic thin film layer comprises one or more light-emitt...
|
|
WO/2010/074327 |
There is provided a halogen-containing organosulfur compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 0, 1 or 2; n represents 0, 1 or 2; A represents an optionally substituted 3-...
|
|
WO/2010/072770 |
The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition ...
|
|
WO/2010/074065 |
Disclosed is a method for manufacturing trimellitic anhydride aryl ester efficiently and with high yield, wherein a carboxylic acid lithium salt is used as a catalyst when an ester exchange reaction is performed with a carboxylic acid ar...
|
|
WO/2010/075437 |
The present invention relates to systems and methods for producing fuels and fuel precursors from carbohydrates. In an embodiment the invention includes a method of producing 5-hydroxymethylfurfural (HMF), including contacting a sacchari...
|
|
WO/2010/069150 |
The para-hydrobenzene acrylic acid derivatives of formula (I) and pharmaceutically acceptable salts, preparation methods, their pharmaceutical compositions and uses for preparing drugs for treating and preventing inflammations or disease...
|
|
WO/2010/070910 |
Disclosed is a 1-heterodiene derivative represented by the formula (2); or, a salt thereof. In formula (2), W represents a hydrogen atom or the like; A, an oxygen atom or the like; R1, a C1-6 alkyl group or the like that is unsubstituted...
|
|
WO/2010/071122 |
Disclosed is an industrial method for manufacturing an intermediate body of a compound which demonstrates an activated blood-clotting factor X inhibitory effect, and which is useful as a thrombotic disease preventive agent and/or therape...
|
|
WO/2010/071745 |
A process is provided for the synthesis of furan and related compounds by vapor phase decarbonylation of furfural and derivatives. The reaction rate, conversion, and selectivity are enhanced by adding water to the feed. The process can b...
|
|
WO/2010/070615 |
Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2...
|
|
WO/2010/068171 |
The present invention relates to a new and more efficient process suitable for large scale preparation of 3-[(2R)tetrahydrofuran-2-ylmethyl]-2-thioxo-1,2,3,7-tetrahyd
ro-6H-purin-6-one.
|
|
WO/2010/068500 |
Described herein are 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl
) propionic acid γ-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and usi...
|
|
WO/2010/067441 |
Disclosed is a practical method for efficiently producing an alcohol compound by hydrogenating an aldehyde by using a homogeneous copper catalyst which is an easily-available low-cost metal species. Specifically disclosed is a method for...
|
|
WO/2010/068500 |
Described herein are 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl
) propionic acid γ-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and usi...
|
|
WO/2010/066847 |
The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.
|
|
WO/2010/067442 |
Disclosed is a practical method for efficiently producing an alcohol compound by hydrogenating an aldehyde by using a homogeneous copper catalyst which is an easily-available low-cost metal species. Specifically disclosed is a method for...
|
|
WO/2010/064871 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells including the same. The organic electroluminescent compound provides superior luminous efficiency and excellent color...
|
|
WO/2010/063773 |
The present invention relates to novel 4- (heterocycloalkyl) benzene- 1, 3-diol compounds corresponding to general formula (I) below: to the compositions containing same, to the process for the preparation thereof and to the use thereof ...
|
|
WO/2010/063471 |
The invention relates to cydopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders.
|
